BCIQ Profiles

Company Profile Report
0706 QT
BioCentury & Getty Images

Product Development

July 6 Quick Takes: Ocugen eyes BLA following Phase III COVID vaccine readout; plus SCOTUS, Provention, British Patient Capital and more

Jul 7, 2021 | 1:28 AM GMT

The COVAXIN COVID-19 vaccine from Ocugen Inc. was 77.8% effective against symptomatic disease and 93.4% effective against severe infection in a Phase III study in India,

Read the full 572 word article

How to gain access

Continue reading with a
two-week free trial.